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Abstract
Background The amplicon on 8p11.2 is reported to be found in
up to 10% of breast carcinomas. It has been demonstrated
recently that this amplicon has four separate cores. The second
core encompasses important oncogene candidates, including
the fibroblast growth factor receptor 1 (FGFR1) gene. Recent
studies have demonstrated that specific FGFR1 amplification
correlates with gene expression and that FGFR1 activity is
required for the survival of a FGFR1 amplified breast cancer cell
line.
Methods  FGFR1  amplification was analysed in tissue
microarrays comprising a cohort of 880 unselected breast
tumours by means of chromogenic in situ hybridisation using
inhouse-generated  FGFR1-specific probes. Chromogenic in
situ  hybridisation signals were counted in a minimum 30
morphologically unequivocal neoplastic cells. Amplification was
defined as >5 signals per nucleus in more than 50% of cancer
cells or when large gene copy clusters were seen.
Results  FGFR1  amplification was observed in 8.7% of the
tumours and was significantly more prevalent in patients >50
years of age and in tumours that lacked HER2 expression. No
association was found with other histological parameters.
Survival analysis revealed FGFR1  amplification as an
independent prognostic factor for overall survival in the whole
cohort. Subgroup analysis demonstrated that the independent
prognostic impact of FGFR1  amplification was only seen in
patients with oestrogen-receptor-positive tumours, where
FGFR1 amplification was the strongest independent predictor
of poor outcome.
Conclusion Given that up to 8.7% of all breast cancers harbour
FGFR1  amplification and that this amplification is an
independent predictor of overall survival, further studies
analysing the FGFR1 as a potential therapeutic target for breast
cancer patients are warranted.
Introduction
Amplification of 8p11.2-p12 is reported to be found in up to
10–15% of all breast cancers [1-5]. For a long time it was
believed that the fibroblast growth factor receptor 1 (FGFR1)
would be the target oncogene of 8p11.2-p12 amplifications
[1,2,5,6]. Recent studies, however, have called into question
the role of FGFR1 as the 'amplicon driver', given that not all
cell lines and breast cancers with 8p11.2-p12 amplification
overexpressed the FGFR1 gene and that FGFR1 protein and
mRNA expression was much more pervasive than gene ampli-
fication [7-9]. Other oncogene candidates for the amplicon on
8p11.2-p12 have been put forward, including zinc finger pro-
tein 703 (FLJ14299), SPFH domain family member 2
(SPFH2, also known as C8orf2), subunit of RNA polymerase
III transcription initiation factor (BRF2) and RAB11 family inter-
acting protein 1 (RAB11FIP1) [7].
Gelsi-Boyer and colleagues [3] have demonstrated more
recently that the 8p11.2-p12 amplicon is much more complex
than previously anticipated and that it comprises at least four
CISH = chromogenic in situ hybridisation; CK = cytokeratin; ER = oestrogen receptor; FGFR1 = fibroblast growth factor receptor 1; NPI = Notting-
ham Prognostic Index.Breast Cancer Research    Vol 9 No 2    Elsheikh et al.
Page 2 of 12
(page number not for citation purposes)
independent cores, which can be amplified independently [3].
While FLJ14299, SPFH2, proline synthetase cotranscribed
homologue (PROSC), BRF2, and RAB11FIP1 were associ-
ated with core A1, golgin subfamily a 7 (GOLGA7) was corre-
lated with A3, and MYST histone acetyltransferase 3 (MYST3)
and miR172-resistant version of AP2 (AP2M3) were associ-
ated with A4. The genes whose expression correlated with
amplification of core A2 included LSM1 homologue, U6 small
nuclear RNA associated (LSM1, also known as cancer-asso-
ciated Sm-like (CASM)), DDHD domain containing 2
(DDHD2), phosphatidic acid phosphatase type 2 domain con-
taining 1B (HTPAP), Wolf–Hirschhorn syndrome candidate 1-
like 1 (WHSC1L1), TM2 and FGFR1 [3]. Interestingly, ampli-
fication of core 2, but not the other cores, was associated with
shorter metastasis-free survival [3].
FGFR1 gene encodes a tyrosine kinase receptor that is part
of the fibroblast growth factor and growth factor receptors
family [10-12]. FGFR1 expression has been shown to play piv-
otal roles in mammary development and breast cancer tumour-
igenesis [12,13]. Activation of FGFR1 in a transgenic mouse
model resulted in increased luminal cell proliferation, activation
of mitogen-activated protein kinase and Akt, lateral budding
and, eventually, alveolar hyperplasia and invasive lesions
[11,12]. In addition, we have recently demonstrated that when
core 2 of the 8p11.2-p12 is amplified, the FGFR1 gene shows
increased levels of mRNA and protein expression [14]. Fur-
thermore, we have also determined in vitro that FGFR1 signal-
ling is paramount for the survival of a FGFR1 amplified breast
cancer cell line [14].
The prognostic impact of FGFR1 amplification in breast can-
cer still remains unclear. In previous studies analysing FGFR1
amplification by means of Southern blot or fluorescent in situ
hybridisation, conflicting results were observed: while FGFR1
amplification proved to be associated with positivity for oestro-
gen receptor (ER) in one study [1], Prentice and colleagues
found no association between FGFR1 amplification and clin-
icopathological parameters or patients' survival [4]. More
recently, using probes for both RAB11FIP1  and  FGFR1,
Letessier and colleagues [15] demonstrated that cases with
8p12 amplification have a significantly shorter metastasis-free
survival [15].
Chromogenic in situ hybridisation (CISH) is a technique that
allows for a concurrent analysis of the gene copy number and
morphological features of the cells [16-21]. Although results
obtained with CISH show an excellent concordance with
those obtained with fluorescent in situ hybridisation [21],
CISH has proven useful for high-throughput copy number
assessment, given that it can be easily applied to tissue micro-
arrays and the analysis can be performed with a conventional
light microscope [16-21]. No studies analysing FGFR1 ampli-
fication, as defined by CISH, in a large cohort of breast cancer
patients have so far been performed. Using a previously
described method [18], inhouse probes specific for FGFR1
were generated and we set out to characterise the prevalence
of FGFR1 amplification in a large community-based cohort of
breast cancers and its correlations with traditional clinico-
pathological features, immunohistochemical markers, and dis-
ease-free and overall survival.
Materials and methods
Tissue microarrays
The tissue microarrays comprised a cohort of 880 unselected
breast tumours from patients presenting between 1986 and
1998 entered into the Nottingham Tenovus Primary Breast
Carcinoma Series (447 invasive ductal carcinomas of no spe-
cial type, 183 tubular mixed carcinomas, 25 medullary carcino-
mas, 84 lobular carcinomas, 28 tubular carcinomas, eight
mucinous carcinomas, six cribriform carcinomas, four papillary
carcinomas, 29 mixed no special type and lobular carcinomas,
23 mixed no special type and special-type carcinomas, and six
miscellaneous tumours – histological type not available in 37
cases). Patient management was based on tumour character-
istics by the Nottingham Prognostic Index (NPI) and hormone
receptor status. Patients with an NPI score ≤3.4 received no
adjuvant therapy, and those with a NPI score >3.4 received
tamoxifen if they were ER-positive (± Zoladex if premenopau-
sal) or received classical cyclophosphamide, methotrexate
and 5-fluorouracil if they were ER-negative and fit enough to
tolerate chemotherapy [22]. Full details of the characterisation
of the tissue microarray and the cohort of patients are summa-
rised in Table 1. Tumours were graded according to a modi-
fied Bloom–Richardson scoring system [23] and size was
categorised according to the TNM staging criteria [24]. The
NPI was calculated as previously described [25].
Survival data including the survival time and the disease-free
interval were maintained on a prospective basis. Disease-free
survival was defined as the interval (in months) from the date
of the primary surgical treatment to the first locoregional
(including invasive malignancy and ductal carcinoma in situ) or
distant recurrence. Overall survival was taken as the time (in
months) from the date of the primary surgical treatment to the
time of death from breast cancer. The immunohistochemical
methods and the results on ER, progesterone receptor, cytok-
eratin (CK) 7/8, CK 18, CK 19, CK 5/6, CK 14, HER2 and epi-
dermal growth factor receptor have been previously described
[26,27].
This study was approved by the Nottingham Research Ethics
Committee 2 under the title 'Development of a molecular
genetic classification of breast cancer'.
Chromogenic in situ hybridisation
CISH for FGFR1 gene amplification was performed on 2-μm-
thick tissue microarray sections mounted on polylysine-coated
slides, using an inhouse-generated probe as previously
described [18]. This probe comprises three bacterial artificialAvailable online http://breast-cancer-research.com/content/9/2/R23
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chromosome contigs (RP11-350N15, RP11-148D21 and
RP11-359P11), which map to the region 38.3–38.6 Mb on
chromosome 8p12-p11.23 and encompasses the FGFR1
and part of WHSC1L1. Heat pretreatment of deparaffinised
sections consisted of incubation for 15 minutes at 98°C in
CISH pretreatment buffer (SPOT-light tissue pretreatment kit;
Zymed (South San Francisco, CA, USA) and digestion with
pepsin for 5.5 minutes at room temperature according to the
manufacturer's instructions. Slides were hybridised and devel-
oped as previously described. An appropriate FGFR1 gene-
amplified breast carcinoma control was included in the slide
run.
CISH experiments were analysed by two of the authors (SEE
and ARG) on a multiheaded microscope. Only unequivocal
signals were counted. Signals were evaluated at 400 × mag-
nification and 630 × magnification, and 30 morphologically
unequivocal neoplastic cells in each core were assessed for
the presence of the FGFR1 gene signals. Amplification was
defined as those cases where >50% of the neoplastic cells
harboured either >5 copies of the gene or large gene clusters.
CISH analysis was performed with observers blinded to clin-
icopathological parameters, patients' survival and results of
the immunohistochemical analysis.
Statistical analysis
Statistical analysis was performed using SPSS 13.0 statistical
software (SPSS INC., Chicago, IL, USA). Median follow-up
was defined as the median follow-up for those patients still
alive and disease free at the latest hospital visit. Cutoff values
for the different biomarkers included in this study were chosen
before statistical analysis. Standard cutoff values were used
for established prognostic factors and were the same as for
previously published patient series [27]. All factors were used
as dichotomous covariates in the statistical analysis with the
exception of grade and the NPI, which were categorised into
three groups.
The associations between the FGFR1 amplification and clin-
icopathological parameters were evaluated by the chi-square
test. Confidence intervals of 95% were adopted. A two-sided
P value <0.05 was considered statistically significant. Survival
curves were calculated by the Kaplan–Meier method. Differ-
ences in survival on the basis of FGFR1 amplification were
estimated using the log-rank test. Multivariate Cox regression
analysis was used to evaluate any independent prognostic
effect of the variable on disease-free survival and the overall
survival, which was adjusted by such well-known prognostic
factors as tumour grade, lymph node stage, tumour size, and
ER status.
Table 1
Frequencies and percentages of tumour grades, size, lymph node stage, distant metastasis and patient age in the tissue 
microarrays
Frequency Percentage
Grade
1 191 22.7
2 273 32.4
3 378 44.9
Lymph node stage
0 561 66.7
N1 203 24.1
N2 77 9.2
Tumour size
≤1.5 cm 301 35.7
>1.5 cm 543 64.3
Distance metastasis
M0 717 85.0
M1 127 15.0
Age
≤50 years 299 35.4
>50 years 545 64.6Breast Cancer Research    Vol 9 No 2    Elsheikh et al.
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Results
After excluding the uninformative tissue microarray cores,
results on FGFR1  amplification were available for 496
tumours. Forty-three tumours (8.7%) showed either >5 signals
or large gene clusters in >50% of neoplastic cells (Figure 1).
Complete clinical follow-up information was available for 478
patients for whom FGFR1 CISH results were optimal. The
median follow-up period was 58 months (range 1–192
months). During this period, a total of 73 (14.7%) patients
died from breast cancer. Of all cases, 116 (24.3%) cases
were grade 1, 141 (29.5%) cases were grade 2, and 221
(46.2%) were grade 3. From the available data, 153 (32.2%)
of the patients had lymph-node-positive disease, 130 (27.8%)
had positive vascular invasion, and 311 (65.1%) had tumour
size ≥1.5 cm. Recurrence occurred in 147 cases (30.8%), and
distant metastases developed in 84 cases (17.6%). A total of
149/496 (30%) patients received tamoxifen, 5/496 (1%)
received tamoxifen and Zoladex, and 309/496 (62.3%)
received no endocrine treatment. There was no significant dif-
ference between the disease-free interval (P = 0.761) or over-
all survival (P = 0.225) between those patients that received
hormone therapy compared with those patients that did not. A
total of 48/496 (9.7%) patients received chemotherapy.
Table 2 summarises the associations between FGFR1 gene
amplification and key prognostic and outcome parameters. In
brief, patients with positive FGFR1 amplification were signifi-
cantly more likely to be older than 50 years of age (P < 0.05)
and to develop distant metastasis (P < 0.05). FGFR1 amplifi-
cation showed an inverse correlation with HER2 overexpres-
sion. A trend for lack of progesterone receptor expression and
negativity for basal markers, as defined by Abd El-Rehim and
colleagues [27], was also observed. No associations were
found between FGFR1 amplification and the grade, lymph-
node stage, NPI, expression of ER, low-molecular-weight
cytokeratins (CK 7/8, CK 8 and CK 19) or high-molecular-
weight cytokeratins (CK 5/6 and CK 14) or basal-like pheno-
type as defined by Nielsen and colleagues [28] (that is, ER-
negative and HER2-negative, CK 5/6 and/or epidermal
growth factor receptor-positive).
Kaplan–Meier survival analysis revealed an association
between FGFR1 amplification and a shorter overall survival (P
= 0.01, log-rank test) (Figure 2a). A trend for a shorter dis-
ease-free survival and FGFR1 amplification was found (P <
0.07, log-rank test) (Figure 2b). On multivariate Cox hazard
analysis adjusted for tumour grade, size and lymph node sta-
tus, for ER status, and for FGFR1 amplification, it was found
that the FGFR1 amplification was a significant predictor of
poor overall survival independent of the other known prognos-
tic parameters (P < 0.04) (Table 3).
Subgroup analysis revealed that FGFR1 amplification was an
independent prognostic factor for disease-free survival and
overall survival only in ER-positive tumours (Figure 2c,d and
Table 4). The association between FGFR1 amplification and
poor outcome was maintained in the group of patients that
received endocrine therapy (Figure 2e,f). FGFR1 amplification
in ER-positive disease was the strongest independent risk fac-
tor for poor disease-free survival and overall survival, with a
greater hazard ratio than high histological grade. Patients with
FGFR1  amplification in the ER-positive group were signifi-
cantly more likely to develop distant metastases and were
associated with a lack of progesterone receptor expression (P
< 0.05) (Table 5). In the cohort of ER-positive tumours, no fur-
ther associations between FGFR1  amplification and other
clinicopathological parameters were found. No associations
were seen between FGFR1  amplification and survival of
patients with ER-negative breast cancers.
Discussion
In recent years it has been demonstrated that CISH is a useful
technique to determine gene copy numbers and gene
amplification on formalin-fixed, paraffin-embedded tissue sec-
tions [16-21]. Unlike fluorescent in situ hybridisation, CISH
allows a direct comparison between morphological features of
neoplastic cells and the presence of gene amplification [16-
21]. Furthermore, CISH analysis is relatively quick; in the
present study, the whole analysis of FGFR1 amplification in a
cohort of 880 patients took 2 weeks and, although only one
tissue microarray core per tumour was analysed, 56% cases
rendered optimal results.
We demonstrate in the present study that FGFR1 amplifica-
tion is found in 8.7% of breast cancers, which is in agreement
Figure 1
FGFR1 gene amplification in breast cancer FGFR1 gene amplification in breast cancer. (a) Grade 3 invasive ductal 
carcinoma (haematoxylin and eosin; original magnification × 200) with 
(b) one or two copies of FGFR1 (original magnification × 400; inset: × 
630). (c) Grade 3 invasive ductal carcinoma (haematoxylin and eosin; 
original magnification × 200) harbouring (d) FGFR1 gene amplification 
(original magnification × 400; inset: × 630).Available online http://breast-cancer-research.com/content/9/2/R23
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Table 2
Correlation between FGFR1 gene amplification and the clinicopathological variables
Parameter Number of samples Positive FGFR1 amplification number (%) P value
Age 478 0.027
<50 years 152 7 (4.6)
≥50 years 346 35 (10.1)
Grade 478 Not significant
1 116 10 (8.6)
2 141 12 (8.5)
3 221 20 (9.0)
Size 478 Not significant
≥1.5 cm 311 30 (9.6)
>1.5 cm 167 12 (7.2)
Lymph node stage 475 Not significant
N0 322 28 (8.7)
N1 110 9 (8.2)
N2 43 4 (9.3)
Nottingham Prognostic Index 475 Not significant
Good 175 14 (8.0)
Moderate 239 21 (8.8)
Poor 61 6 (9.8)
Distant metastasis 478 0.050
No 394 30 (7.6)
Definite 84 12 (14.3)
Vascular invasion 467 Not significant
No 337 27 (8.0)
Yes 130 14 (10.8)
Oestrogen receptor 453 Not significant
Negative 140 10 (7.1)
Positive 313 27 (8.6)
Progesterone receptor 449 0.084
Negative 206 22 (10.7)
Positive 243 15 (6.2)Breast Cancer Research    Vol 9 No 2    Elsheikh et al.
Page 6 of 12
(page number not for citation purposes)
HER2 445 0.043
Negative 259 28 (10.8)
Positive 186 10 (5.4)
Androgen receptor 415 Not significant
Negative 188 18 (9.6)
Positive 227 13 (5.7)
Cytokeratin 7/8 467 Not significant
Negative 167 17 (10.2)
Positive 300 24 (8.0)
Cytokeratin 18 396 Not significant
Negative 116 7 (6.0)
Positive 280 23 (8.2)
Cytokeratin 19 464 Not significant
Negative 95 10 (10.5)
Positive 369 30 (8.1)
Cytokeratin 5/6 465 Not significant
Negative 350 34 (9.7)
Positive 115 6 (5.2)
Cytokeratin 14 458 Not significant
Negative 357 33 (9.2)
Positive 101 6 (5.9)
Epidermal growth factor receptor 351 Not significant
Negative 292 26 (8.9)
Positive 59 3 (5.1)
Basal markers [27] 455 Not significant
Negative 311 31 (10.0)
Positive 144 8 (5.6)
Nielsen groups [28] 396 Not significant
HER2 39 3 (7.7)
Basal-like 55 3 (5.5)
Luminal 302 26 (8.6)
Table 2 (Continued)
Correlation between FGFR1 gene amplification and the clinicopathological variablesAvailable online http://breast-cancer-research.com/content/9/2/R23
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with previous studies [1-4,29]. Unlike previous studies where
FGFR1 amplification was determined by Southern blot analy-
sis [1], our results and those obtained with other in situ meth-
ods [3,4,15] did not show any correlation between FGFR1
amplification and low histological grade or positivity for ER. On
the other hand, our results demonstrate that FGFR1 amplifica-
tion is an independent predictor of poor outcome, especially
for patients with ER-positive breast cancers. Interestingly, the
impact of FGFR1 amplification was stronger on overall survival
than disease-free survival (that is, higher hazard ratios on mul-
tivariate analysis). This may stem from the fact that locore-
gional recurrences were included as events for disease-free
survival analysis, and that overall survival considered only
breast-cancer-related deaths as events. Alternatively, this may
reflect the association between FGFR1 amplification and the
development of distant metastasis (P = 0.05) or a shorter sur-
vival after the first distant recurrence event.
Our group [14] and others [3] have demonstrated that when
FGFR1 is specifically amplified (that is, amplification of core
A2 of the 8p11.2-p12 amplicon) it is also overexpressed, and
that FGFR1 signalling is important for the survival of a cell line
that harbours FGFR1  amplification and high-level gene
expression [14,30]. Taken together, these results suggest
Figure 2
Univariate analysis of the prognostic impact of FGFR1 gene amplification overexpression on disease-free survival and overall survival Univariate analysis of the prognostic impact of FGFR1 gene amplification overexpression on disease-free survival and overall survival. (a) Whole 
cohort, disease-free survival. (b) Whole cohort, overall survival. (c) Oestrogen-receptor-positive cases, disease-free survival. (d) Oestrogen-recep-
tor-positive cases, overall survival. (e) Oestrogen-receptor-positive patients that received endocrine therapy, disease-free survival. (f) Oestrogen-
receptor-positive patients that received endocrine therapy, overall survival.Breast Cancer Research    Vol 9 No 2    Elsheikh et al.
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that, in a significant proportion of cases with core A2 amplifi-
cation, FGFR1  may be the actual amplicon driver [6]. We
could not correlate FGFR1 amplification with expression in
this study, as it was not possible to optimise antibodies for
FGFR1 immunohistochemical analysis on tissue microarrays
due to the highly fixation-dependent nature of the commer-
cially available antibodies (data not shown).
The FGFR1 gene encodes a tyrosine kinase receptor that has
been shown to play an important role in mammary gland devel-
opment [12,13,31]. Previous studies have shown in vitro and
in vivo that FGFR1 overexpression has oncogenic properties
[10,12-14,31]. Furthermore, FGFR1 has been implicated in
the tumourigenesis of haematological malignancies, where it is
frequently involved in balanced chromosomal translocations,
including cases of chronic myeloid leukaemia (BCR-FGFR1
fusion) and the 8p11 myeloproliferative syndrome/stem cell
leukaemia–lymphoma syndrome, which is characterised by
myeloid hyperplasia and non-Hodgkin's lymphoma with chro-
mosomal translocations fusing several genes, the most com-
mon being a fusion between ZNF198 and FGFR1 [32]. In
preclinical models, the PKC412 tyrosine kinase inhibitor has
been shown to successfully inhibit the growth of proliferation
of ZNF198-FGFR1-transformed Ba/F3 cells and to prolong
the survival of animals with a ZNF198-FGFR1-induced stem
cell leukaemia–lymphoma syndrome [33]. Targeting FGFR1
signalling with RNA interference or with the SU5402 FGFR1
tyrosine kinase inhibitor has been shown to decrease cell sur-
vival in a breast cancer cell line with FGFR1 amplification [14].
Conclusion
Taken together, our results demonstrate that FGFR1 amplifi-
cation is found in 8.7% of breast cancers and is an independ-
ent predictor of outcome. Although large studies correlating
FGFR1 amplification with mRNA and protein expression are
Table 3
Cox proportional hazards analysis for predictors of overall survival: effects of tumour grade, size, lymph node stage, oestrogen 
receptor status and FGFR1 amplification
Variable Hazard ratio 95% confidence interval P value
Gradea 2.13 1.32–3.44 0.002
Tumour size ≥1.5 cmb 2.17 1.06–4.44 0.034
Positive lymph node stage 3.52 2.17–5.72 <0.001
Positive oestrogen receptor status 0.44 0.26–0.74 0.002
FGFR1 amplification 2.00 1.02–3.92 0.043
aFitted as a linear term; that is, an increase in risk for change in grade of one unit.
bCompared with tumour size <1.5 cm.
Table 4
Cox proportional hazards analysis for predictors of disease-free and overall survival: effects of tumour grade, size, lymph node 
stage, oestrogen receptor (ER) status and FGFR1 status in ER-positive and ER-negative tumours
Variable ER-positive tumours ER-negative tumours
Hazard ratio 95% confidence interval P value Hazard ratio 95% confidence interval P value
Disease-free interval
Gradea 1.387 1.027–1.874 0.033 1.001 0.637–1.574 0.996
Tumour size ≥1.5 cmb 1.551 0.926–2.595 0.095 2.348 1.092–5.052 0.029
Positive lymph node stage 1.407 0.879–2.252 0.155 2.597 1.563–4.315 0.000
FGFR1 amplification 2.250 1.184–4.274 0.013 1.104 0.440–2.774 0.833
Overall survival
Gradea 2.600 1.471–4.594 0.001 1.673 0.731–3.829 0.223
Tumour size ≥1.5 cmb 2.124 0.792–5.697 0.134 2.594 0.911–7.387 0.074
Positive lymph node stage 1.973 0.953–4.083 0.067 5.124 2.646–9.924 0.000
FGFR1 amplification 3.389 1.374–8.358 0.008 1.278 0.450–3.624 0.645
aFitted as a linear term; that is, an increase in risk for change in grade of one unit.
bCompared with tumour size <1.5 cm.Available online http://breast-cancer-research.com/content/9/2/R23
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Table 5
Correlation between FGFR1 gene amplification and the clinicopathological variables in the oestrogen-receptor-positive group
Parameter Number of samples Positive FGFR1 amplification number (%) P value
Age 313 Not significant
<50 years 95 6 (6.3)
≥50 years 218 21 (9.6)
Grade 313 Not significant
19 9 8  ( 8 . 1 )
2 120 10 (8.3)
39 4 9  ( 9 . 6 )
Size 313 Not significant
≥1.5 cm 188 19 (10.1)
<1.5 cm 125 8 (6.4)
Lymph node stage 311 Not significant
N0 214 19 (8.9)
N1 74 6 (8.2)
N2 23 2 (9.3)
Nottingham Prognostic Index 311 Not significant
Good 148 11 (7.4)
Moderate 133 14 (10.5)
Poor 30 2 (6.7)
Distant metastasis 313 0.032
No 273 20 (7.3)
Definite 40 7 (17.5)
Vascular invasion 303 Not significant
No 224 18 (8)
Yes 79 8 (10.1)
Progesterone receptor 305 0.05
Negative 80 11 (13.8)
Positive 225 15 (6.7)Breast Cancer Research    Vol 9 No 2    Elsheikh et al.
Page 10 of 12
(page number not for citation purposes)
HER2 299 0.063
Negative 179 20 (11.2)
Positive 120 6 (5.0)
Androgen receptor 283 0.08
Negative 90 11 (12.2)
Positive 193 12 (6.2)
Cytokeratin 7/8 310 Not significant
Negative 73 8 (11)
Positive 237 19 (8.0)
Cytokeratin 18 269 Not significant
Negative 46 1 (2.2)
Positive 223 21 (9.4)
Cytokeratin 19 308 Not significant
Negative 33 4 (12.1)
Positive 275 22 (8.0)
Cytokeratin 5/6 306 Not significant
Negative 261 24 (9.2)
Positive 45 2 (4.4)
Cytokeratin 14 299 Not significant
Negative 252 23 (9.1)
Positive 47 2 (4.3)
Epidermal growth factor receptor 242 Not significant
Negative 209 19 (9.1)
Positive 33 2 (6.1)
Basal markers [27] 297 Not significant
Negative 234 22 (9.4)
Positive 63 3 (4.8)
Table 5 (Continued)
Correlation between FGFR1 gene amplification and the clinicopathological variables in the oestrogen-receptor-positive groupAvailable online http://breast-cancer-research.com/content/9/2/R23
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still needed, the functional data demonstrating that FGFR1
signalling is required for the survival of breast cancer cells har-
bouring FGFR1 amplification [14], the relatively high preva-
lence of FGFR1  amplification in breast cancer and the
independent prognostic information provided by FGFR1
amplification status support the idea that this gene may be a
useful therapeutic target for a subgroup of breast cancer
patients with FGFR1 gene amplification [14].
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